Drug harms in the UK: a multicriteria decision analysis - PubMed (original) (raw)

. 2010 Nov 6;376(9752):1558-65.

doi: 10.1016/S0140-6736(10)61462-6. Epub 2010 Oct 29.

Affiliations

• PMID: 21036393
• DOI: 10.1016/S0140-6736(10)61462-6

Drug harms in the UK: a multicriteria decision analysis

David J Nutt et al. Lancet. 2010.

Abstract

Background: Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK.

Methods: Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the harms to others. Drugs were scored out of 100 points, and the criteria were weighted to indicate their relative importance.

Findings: MCDA modelling showed that heroin, crack cocaine, and metamfetamine were the most harmful drugs to individuals (part scores 34, 37, and 32, respectively), whereas alcohol, heroin, and crack cocaine were the most harmful to others (46, 21, and 17, respectively). Overall, alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places.

Interpretation: These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs. However, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.

Funding: Centre for Crime and Justice Studies (UK).

Copyright © 2010 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Comment in

• Ranking of drugs: a more balanced risk-assessment.
  van Amsterdam J, van den Brink W. van Amsterdam J, et al. Lancet. 2010 Nov 6;376(9752):1524-5. doi: 10.1016/S0140-6736(10)62000-4. Epub 2010 Oct 29. Lancet. 2010. PMID: 21036391 No abstract available.
• Drugs and harm to society.
  Peto R, Boreham J. Peto R, et al. Lancet. 2011 Feb 12;377(9765):551-2; author reply 555. doi: 10.1016/S0140-6736(11)60193-1. Lancet. 2011. PMID: 21315936 No abstract available.
• Drugs and harm to society.
  Britton J, McNeill A, Arnott D, West R, Godfrey C. Britton J, et al. Lancet. 2011 Feb 12;377(9765):551; author reply 555. doi: 10.1016/S0140-6736(11)60192-X. Lancet. 2011. PMID: 21315937 No abstract available.
• Drugs and harm to society.
  Claridge LC. Claridge LC. Lancet. 2011 Feb 12;377(9765):552; author reply 555. doi: 10.1016/S0140-6736(11)60194-3. Lancet. 2011. PMID: 21315938 No abstract available.
• Drugs and harm to society.
  Bird SM. Bird SM. Lancet. 2011 Feb 12;377(9765):552-3; author reply 555. doi: 10.1016/S0140-6736(11)60195-5. Lancet. 2011. PMID: 21315939 No abstract available.
• Drugs and harm to society.
  Viskaduraki M, Mamuneas D. Viskaduraki M, et al. Lancet. 2011 Feb 12;377(9765):553-4; author reply 555. doi: 10.1016/S0140-6736(11)60196-7. Lancet. 2011. PMID: 21315940 No abstract available.
• Drugs and harm to society.
  Hewstone M. Hewstone M. Lancet. 2011 Feb 12;377(9765):554; author reply 555. doi: 10.1016/S0140-6736(11)60197-9. Lancet. 2011. PMID: 21315941 No abstract available.
• Drugs and harm to society.
  Hawkey C, Rhodes J, Gilmore I, Sheron N. Hawkey C, et al. Lancet. 2011 Feb 12;377(9765):554; author reply 555. doi: 10.1016/S0140-6736(11)60198-0. Lancet. 2011. PMID: 21315942 No abstract available.
• Questioning the method and utility of ranking drug harms in drug policy.
  Rolles S, Measham F. Rolles S, et al. Int J Drug Policy. 2011 Jul;22(4):243-6. doi: 10.1016/j.drugpo.2011.04.004. Epub 2011 Jun 8. Int J Drug Policy. 2011. PMID: 21652195

Similar articles

• The Australian drug harms ranking study.
  Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, Egerton-Warburton D, Karro J, Kim C, Lenton S, Lubman DI, Pastor A, Rundle J, Ryan J, Gordon P, Sharry P, Nutt D, Castle D. Bonomo Y, et al. J Psychopharmacol. 2019 Jul;33(7):759-768. doi: 10.1177/0269881119841569. Epub 2019 May 13. J Psychopharmacol. 2019. PMID: 31081439
• Development of a rational scale to assess the harm of drugs of potential misuse.
  Nutt D, King LA, Saulsbury W, Blakemore C. Nutt D, et al. Lancet. 2007 Mar 24;369(9566):1047-53. doi: 10.1016/S0140-6736(07)60464-4. Lancet. 2007. PMID: 17382831 Review.
• Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
  Howard S, Scott IA, Ju H, McQueen L, Scuffham PA. Howard S, et al. Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042. Aust Health Rev. 2019. PMID: 30205873
• The New Zealand drug harms ranking study: A multi-criteria decision analysis.
  Crossin R, Cleland L, Wilkins C, Rychert M, Adamson S, Potiki T, Pomerleau AC, MacDonald B, Faletanoai D, Hutton F, Noller G, Lambie I, Sheridan JL, George J, Mercier K, Maynard K, Leonard L, Walsh P, Ponton R, Bagshaw S, Muthukumaraswamy S, McIntosh T, Poot E, Gordon P, Sharry P, Nutt D, Boden J. Crossin R, et al. J Psychopharmacol. 2023 Sep;37(9):891-903. doi: 10.1177/02698811231182012. Epub 2023 Jun 23. J Psychopharmacol. 2023. PMID: 37353972 Free PMC article.
• The children of mama coca: coca, cocaine and the fate of harm reduction in South America.
  Bastos FI, Caiaffa W, Rossi D, Vila M, Malta M. Bastos FI, et al. Int J Drug Policy. 2007 Mar;18(2):99-106. doi: 10.1016/j.drugpo.2006.11.017. Epub 2007 Jan 5. Int J Drug Policy. 2007. PMID: 17689352 Review.

Cited by

• Neuropsychiatric Disorders: Bridging the Gap Between Neurology and Psychiatry.
  Taslim S, Shadmani S, Saleem AR, Kumar A, Brahma F, Blank N, Bashir MA, Ansari D, Kumari K, Tanveer M, Varrassi G, Kumar S, Raj A. Taslim S, et al. Cureus. 2024 Jan 4;16(1):e51655. doi: 10.7759/cureus.51655. eCollection 2024 Jan. Cureus. 2024. PMID: 38313968 Free PMC article. Review.
• Alcohol use disorder and treatment receipt among individuals aged 50 years and older: Other substance use and psychiatric correlates.
  Choi NG, DiNitto DM. Choi NG, et al. J Subst Abuse Treat. 2021 Dec;131:108445. doi: 10.1016/j.jsat.2021.108445. Epub 2021 Apr 29. J Subst Abuse Treat. 2021. PMID: 34098300 Free PMC article.
• Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol.
  Butler M, Bird C, Maggio C, Durden A, Modlin N, Campbell-Coker K, Edwards M, Pick S, Millman LSM, Lowery E, Bhagavan C, Kanaan R, Golder D, Mildon B, Mehta M, Rucker J, Nicholson TR. Butler M, et al. Wellcome Open Res. 2024 Jul 24;9:401. doi: 10.12688/wellcomeopenres.22543.1. eCollection 2024. Wellcome Open Res. 2024. PMID: 39372842 Free PMC article.
• Patterns of alcohol use, their correlates, and impact in male drinkers: a population-based survey from Goa, India.
  Pillai A, Nayak MB, Greenfield TK, Bond JC, Nadkarni A, Patel V. Pillai A, et al. Soc Psychiatry Psychiatr Epidemiol. 2013 Feb;48(2):275-82. doi: 10.1007/s00127-012-0538-1. Epub 2012 Jul 3. Soc Psychiatry Psychiatr Epidemiol. 2013. PMID: 22752108 Free PMC article.
• Drug Use Disorders and Violence: Associations With Individual Drug Categories.
  Zhong S, Yu R, Fazel S. Zhong S, et al. Epidemiol Rev. 2020 Jan 31;42(1):103-116. doi: 10.1093/epirev/mxaa006. Epidemiol Rev. 2020. PMID: 33005950 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal